Brief: Intellia Therapeutics Q3 Net Income USD -135.712 Million
07/11/2024 12:30
Nov 07 (Reuters) - Intellia Therapeutics Q3 basic EPS USD -1.34. * Q3 collaboration revenue USD 9.111 million * Q3 operating expenses USD 153.881 million * Q3 operating income USD -144.77 million
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)